Poor food choices during GLP-1 therapy create a predictable set of problems
The combination of reduced oral intake from appetite suppression and fluid losses from gastrointestinal symptoms creates a vulnerable period, especially during the first 812 weeks of therapy or following dose increases
Specifications Strength 12 mg/vial Form Lyophilized powder Presentation Single-dose sterile vial Purity 98% by HPLC Testing Identity, potency, sterility Storage Refrigerate, protect from light Release Certificate of analysis per lot Prescribing information How Retatrutide is supplied
Some people start with a GLP-1 medication and later add insulin
Other research has shown conflicting results, with some studies suggesting neutral or even protective effects of GLP-1 medications on diabetic eye disease over longer follow-up periods
Antioxidants can then reduce inflammation and improve blood circulation so that clots are less likely to form